[1] Deng Y D, Peng X B, Zhao R R, et al. The intestinal microbial community dissimilarity in hepatitis B virus-related liver cirrhosis patients with and without at alcohol consumption[J].Gut Pathog, 2019, 11(1):58.
[2] Zheng Y B, Xie S B, Xie D Y, et al. 827 prognosticating value of altered serum-soluble CD40L levels and CD40 expression on monocytes in fulminant hepatic failure[J]. J Hepatol, 2010, 52(Suppl 1):S322-S323.
[3] Lange C M, Bechstein W O, Berg T, et al. Acute-on-chronic liver failure[J]. Visc Med, 2018, 34(4):296-300.
[4] Li C, Su H B, Liu X Y, et al. Clinical characteristics and 28-d outcomes of bacterial infections in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. World J Clin Cases, 2020, 8(6):1042-1055.
[5] Wang C, Ma D Q, Luo S, et al. Incidence of infectious complications is associated with a high mortality in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. World J Clin Cases, 2019, 7(16):2204-2216.
[6] Zhai X R, Tong J J, Wang H M,et al. Infection deteriorating hepatitis B virus related acute-on-chronic liver failure: a retrospective cohort study[J]. BMC Gastroenterol, 2020, 20(1):320.
[7] 杨淑殷,李淑婷,薛峰,等.乙型肝炎相关慢加急性肝衰竭合并脓毒症的病理特征[J].中国肝脏病杂志(电子版),2014,6(2):6-9.
[8] Zheng W, Ye B, Liang X, et al. Hepatic macrophages are the cell source of hepatic procalcitonin in acute liver failure[J]. Cell Physiol Biochem,2018, 47(3):1133-1140.
[9] Yadav P, Trehanpati N, Maiwall R, et al. Soluble factors and suppressive monocytes can predict early development of sepsis in acute-on-chronic liver failure[J]. Hepatol Commun,2022, 6(8):2105-2120.
[10] Carpio R, Zapata J, Spanuth E, et al. Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department[J].Clin Chim Acta,2015, 450:169-175.
[11] Chen J, Huang Z B, Li H, et al. Early diagnostic biomarkers of sepsis for patients with acute-on-chronic liver failure: a multicenter study[J].Infect Dis Ther, 2021,10(1):281-290.
[12] 田小利,吴松林,王波,等.COSSH-ACLFs评分模型对HBV相关慢加急性肝衰竭患者短期预后的预测价值[J]. 临床肝胆病杂志,2020,36(6):1258-1262.
[13] Zhang Z, Yang Z, Cheng Q, et al. Establishment and validation of a prognostic model for hepatitis B virusrelated acute-on-chronic liver failure patients with bacterial infection[J]. Hepatol Int, 2022, 16(1):38-47.
[14] Kumar A, Roberts D, Wood K E, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock[J]. Crit Care Med, 2006, 34(6):1589-1596.
[15] 魏琦,杨静楠,何学良,等.粪便菌群移植在慢性乙肝治疗中的作用及机制[J].中国病理生理杂志,2020,36(10):1833-1843.
[16] 高安,徐玉静,陆圣威,等.粪菌移植对慢加急性肝衰竭小鼠模型肠道菌群的影响[J].临床肝胆病杂志,2021,37(6):1379-1385.
[17] 盖晓伟.粪菌移植重建脓毒症小鼠肠道菌群及其对肠粘膜屏障的保护作用[D].河北医科大学,2020.
[18] Bruning R, Dykes H, Jones T W, et al. Beta-adrenergic blockade in critical illness[J]. Front Pharmacol, 2021, 12:735841.
[19] Bae J S, Lee W, Son H N, et al. Anti-transforming growth factor β-induced protein antibody ameliorates vascular barrier dysfunction and improves survival in sepsis[J]. Acta Physiol (Oxf), 2014, 212(4):306-315.
[20] Zhao Q, Wu C S, Fang Y, et al. Glucocorticoid regulates NLRP3 in acute-on-chronic hepatitis B liver failure[J]. Int J Med Sci, 2019, 16(3):461-469.
[21] Chen Y Y, Li H, Xu B Y, et al. Chinese Chronic Liver Failure (CLIF) Consortium. Plasma exchange-based non-bioartificial liver support system improves the short-term outcomes of patients with hepatitis B virus-associated acute-on-chronic liver failure: a multicenter prospective cohort study[J]. Front Med (Lausanne), 2021, 8:779744.
[22] 中华医学会肝病学分会重型肝病与人工肝学组,白浪,陈煜,等.人工肝血液净化技术临床应用专家共识(2022年版)[J].实用肝脏病杂志,2022,25(3):457-468.
[23] Fernández J, Saliba F. Liver transplantation in patients with ACLF and multiple organ failure: time for priority after initial stabilization[J]. J Hepatol, 2018, 69(5):1004-1006.
[24] Shi M, Zhang Z, Xu R, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients[J]. Stem Cells Transl Med, 2012, 1(10):725-731.
[25] Lin B L, Chen J F, Qiu W H, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial[J]. Hepatology, 2017, 66(1):209-219. |
